This VGR expired on 5/11/2016.

Members of the multidisciplinary care team who diagnose and manage NSCLC must take into consideration histological subtypes and molecular/biomarker analysis that guide appropriate treatment decisions to individualize treatment approaches and improve patient outcomes. Clinicians also need to remain apprised of emerging data offering additional treatment options for NSCLC, specifically in the advanced stage when the disease is typically diagnosed.
 
Through a case-based approach, this Virtual Grand Rounds will address educational and performance gaps related to the histological and pathological parameters and biomarkers that guide clinical decisions on the appropriate treatment of patients with NSCLC and as a result, help participants make highly informed decisions for their patients. 

This activity includes:

  • CME/CE-Certified Virtual Grand Rounds for 1.0 AMA PRA Category 1 CreditTM / 1.0 ANCC Contact Hour

Through a case-based approach, this Virtual Grand Rounds will address educational and performance gaps related to the histological and pathological parameters and biomarkers that guide clinical decisions on the appropriate treatment of patients with NSCLC and as a result, help participants make highly informed decisions for their patients.

TARGET AUDIENCE: 
This activity is intended for pathologists, medical oncologists, radiation oncologists, surgical oncologists, oncology nurses, pulmonologists, and other members of the multidisciplinary healthcare team responsible for the diagnosis and management of non–small cell lung cancer (NSCLC).

Method of Participation: Internet

Instructions to receive credit: To receive credit for this activity, the participant must complete the post-test with a score of 70% or better and the activity evaluation. The certificate will be made available immediately.

Estimated time to complete activity: 1 hour

Contact the Postgraduate Institute for Medicine (PIM) at: http://pimed.com

LEARNING OBJECTIVES: 
At the conclusion of this activity, participants should be better able to:

  • Describe the importance and implications of obtaining adequate tissue samples in defining appropriate NSCLC treatment
  • Implement molecular testing strategies according to guidelines to tailor treatment decisions in patients with NSCLC
  • Evaluate current therapeutic strategies tailored to individual subtypes and how they impact subsequent treatment
  • Integrate evidence-based clinical data and treatment guidelines into the selection of current therapeutic options for the management of NSCLC
  • Assess the latest clinical trial data on investigational therapeutic options for patients with NSCLC
  • Provide appropriate care and counsel for patients and their families.
Presented By
 
Mark A. Socinski, MD
Professor of Medicine and Thoracic Surgery
Director, Lung Cancer Section, Division of Hematology/Oncology
Clinical Associate Director, Lung SPORE
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh
UPMC Cancer Pavilion
Pittsburgh, Pennsylvania

Physician Continuing Medical Education
ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and AXIS Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Medical Education
CREDIT DESIGNATION

This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine. 

ACCREDITATION STATEMENT
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant: 

Mark A. Socinski, MD, reported a financial interest/relationship or affiliation in the form ofSpeakers’ bureau: Celgene Corporation; Genentech, Inc.; Contracted research: Bristol-Myers Squibb Company; Celgene Corporation; Clovis Oncology; GlaxoSmithKline; Pfizer, Inc.; PUMA Biotechnology; Synta Pharmaceuticals Corp. 

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Linda Gracie-King, MS; Deborah Middleton, MS; and Diedrea White, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

SAFEGUARDS AGAINST COMMERCIAL BIAS
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:

  • 1. Fair balance 
    • a. Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter 
    • b. No single product or service is overrepresented when other equal competing products or services are available for inclusion
  • 2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
  • 3. Appropriateness of patient care recommendations made to learners

Fee Information

There is no fee for this educational activity.

Jointly provided by

This activity is supported by an educational grant from Genentech.